BioMarin Q1 Revenue Beats Estimates, Full-Year Outlook Raised Post-Amicus Deal
Summary
BioMarin Pharmaceutical reported strong first-quarter results, with revenue reaching $766 million, exceeding analyst estimates of $756 million. This performance was driven by robust sales of existing enzyme therapies and the initial contribution from the recently acquired Amicus Therapeutics portfolio. Following the completion of the Amicus acquisition last week, BioMarin has raised its 2026 total revenue guidance to $3.825 billion-$3.925 billion, a significant increase from the previous range of $3.325 billion-$3.425 billion. While adjusted EPS also surpassed expectations, the company slightly lowered its 2026 Non-GAAP diluted EPS guidance to $4.85-$5.05, citing higher operating costs and acquisition-related expenses. This update provides the first financial insights into the combined entity and its forward-looking prospects, indicating a positive revenue trajectory despite some near-term pressure on profitability.
At the time of this announcement, BMRN was trading at $55.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $50.76 to $66.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.